Your session is about to expire
← Back to Search
MK-0616 for High Cholesterol
Study Summary
This trial tests a drug to lower cholesterol in adults with high cholesterol. Results will measure if it's better than placebo. #cholesterol #clinicaltrial
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 381 Patients • NCT05261126Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What adverse effects have been associated with MK-0616?
"Our experts at Power gave MK-0616 a 3 due to the existence of evidence for its efficacy and safety as it has gone through numerous trials in Phase 3."
How many geographic areas are offering this research opportunity?
"Presently, there are 41 locations around the USA that are hosting this medical trial. These sites include Phoenix, Banning and Sacramento in addition to 38 other spots. To reduce travel needs it is best if you pick a clinic close by when enrolling."
Are participants being accepted to join this research endeavor?
"Affirmative. Information on clinicaltrials.gov indicates that this study, which was first published on August 10th 2023, is currently recruiting patients. In total, 2760 participants must be enrolled from 41 separate research centres."
How many individuals have been accepted to participate in this trial?
"Indeed, the data referenced on clinicaltrials.gov supports that this trial is actively enlisting patients. This medical experiment was first announced on August 10th 2023 and has been updated most recently as of August 28th 2023. The study requires 2,760 volunteers to be sourced from 41 distinct sites."
Could you elaborate on the pivotal aims of this research project?
"According to Merck Sharp & Dohme LLC, the primary objective of this trial will be measured over a Baseline and Week 24 timeframe. This involves tracking the amount of participants who experience one or more adverse events (AEs). Furthermore, secondary outcomes such as mean percent change from baseline in non-HDL-C at Week 24 and mean percent change from baseline in ApoB at Week 24 shall also be examined. Lastly, the trial sponsor plans on evaluating the percentage change from baseline in lipoprotein(a) (Lp[a]) at Week 24 through blood samples collected during both Baseline and Week 24 time"
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger